# Tempus Announces Eleven Abstracts Accepted for Presentation at the 2021 American Society of Clinical Oncology Annual Meeting

June 1, 2021

Tempus, a leader in artificial intelligence and precision medicine, today announced eleven abstracts accepted for presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting taking place virtually from June 4 – 8.

"These high impact ASCO presentations from Tempus collaborators and investigators illustrate the power of over 35 petabytes worth of clinical and molecular data collected since Tempus started five years ago," said Dr. Kimberly Blackwell, Chief Medical Officer at Tempus. "By combining extensive tumor and germline genomic profiling with just-in-time clinical trial matching in our TIME Trial Network, Tempus is bringing the right treatments to patients facing cancer in a data-driven and expedited way. I am really excited to share how our multi-modal data is helping transform precision cancer care."

One abstract selected for oral presentation and four abstracts selected for poster presentation at ASCO 2021 are highlighted below. The complete list of Tempus-affiliated abstracts and poster presentations can be found at www.tempus.com/publications.

- **Multimodal Profiling of Biliary Tract Cancers Detects Potentially Actionable Biomarkers and Differences in Immune Signatures Between Subtypes**
    - **Overview:** This study examined the relationship between the mutational landscape and immune-related RNA signatures of different biliary tract cancer subtypes, including intrahepatic, extrahepatic cholangiocarcinoma and gallbladder cancers. Based on RNA signatures, gallbladder cancers had higher expression of select immune signatures compared to intrahepatic cancers.
    - *This abstract has been accepted for oral presentation in the "Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary" session on June 5 from 1:45 – 4:45 pm CST.*
- **Landscape of KRASG12C, Associated Genomic Alterations, and Interrelation With Immuno-Oncology (IO) Biomarkers**
    - **Overview:** Using Lens, Tempus' cloud-based data and analytics platform for drug discovery and development, the de-identified records of 79,004 patients diagnosed with various cancer types who underwent Tempus xT and xF next generation sequencing were analyzed to study the association between *KRAS* variants and cancer subtypes. Tumors harboring *KRAS*G12C were associated with smoking status and had significantly higher tumor mutational burden and programmed death-ligand 1 expression, which are important markers for immunotherapy.
    - *This abstract has been accepted for poster presentation in the "Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology" track and will be available on June 4 at 7:00 am CST.*
- **The TIME Trial Network to Facilitate Rapid Clinical Trial Activation, Patient Screening, and Enrollment in Molecularly Targeted Trials**
    - **Overview:** Tempus' TIME Trial® Network was established to increase access and participation in clinical trials by applying a rapid just-in-time activation model. In the last quarter of 2020, six unique interventional clinical trials were activated across eight US states in the TIME Trial® Network. Over a 3-month period, on average, TIME Trial® sites were activated in 9.4 days (compared to the 20+ week industry-wide average), and patient consent was completed in 4.5 days.
    - *This abstract has been accepted for poster presentation in the "Care Delivery and Regulatory Policy" track and will be available on June 4 at 7:00 am CST.*
- **Rate of Incidental Germline Findings Detected by Tumor-Normal Matched Sequencing in Cancer Types Lacking Hereditary Cancer Testing Guidelines**

- **Overview:** This study analyzed 21,395 de-identified records from patients across select cancer types sequenced using Tempus xT Tumor-normal matched approach. Incidental P/LP germline variants were detected in 6.4% of patients diagnosed with the 6 select cancer types that lack hereditary cancer testing guidelines, with the highest prevalence in patients with bladder (7.9%), brain (6.5%), and lung (6.5%) cancers. The identification of such germline findings may have clinical implications for the patients, as well as at-risk family members, resulting in the opportunity for genetic counseling and risk-stratified intervention.
- *This abstract has been accepted for poster presentation in the "Prevention, Risk Reduction, and Hereditary Cancer" track and will be available on June 4 at 7:00 am CST.*

- **Comprehensive Genomic Profiling in Advanced/Metastatic Colorectal Cancer: Number Needed to Test and Budget Impact of Expanded First-Line Use**
  - **Overview:** A decision analytical model, based on Tempus xT, was developed to determine the impact of first-line genomic profiling in detection of actionable alterations in metastatic colorectal cancer, along with the associated diagnostic testing costs in a modeled US health plan setting of 5 million lives. Replacing 20% of standard of care testing with Tempus xT was associated with a small incremental testing cost, but led to identification of actionable alterations in a meaningful number of patients.
  - *This abstract has been accepted for publication in the "Health Services Research and Quality Improvement" session and will be available on June 4 at 7:00 am CST.*

**About Tempus**

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.